Harnessing Telemedicine to Improve Alcohol Use Disorder Outcomes in Primary Care Patients
Launched by UNIVERSITY OF MICHIGAN · Jun 6, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at new ways to help people who struggle with alcohol use disorder (AUD) manage their health and make positive changes. The study aims to find out if programs delivered through telemedicine—like video calls or phone conversations—can help participants set goals and learn skills to better handle their alcohol use and overall well-being. Participants will be divided into two groups: one will receive the new telehealth program, and the other will receive enhanced usual care, which means they will still get standard support but not the new program.
To be eligible for the study, participants need to be between 18 and 75 years old, currently experiencing issues with alcohol use, and have been drinking at least three days a week for the past month. They must also have a device that allows for video or phone calls. Those who have recently received therapy for alcohol use, are at high risk for serious withdrawal symptoms, or cannot understand English will not be able to participate. Everyone in the study will have follow-up visits for up to a year to see how they are doing. This trial will help researchers understand better ways to provide support and information to those facing challenges with alcohol use.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Current Diagnostic and Statistical Manual (DSM) -5 alcohol use disorder (AUD) based on alcohol symptom checklist
- • An average of 3 or more drinking days per week for the past 30 days
- • Have regular access to a device with video capabilities or a phone to use for study related calls
- Exclusion Criteria:
- • Inability to speak or understand English
- • Conditions that preclude informed consent or understanding of assessment or intervention content
- • Past 90-day AUD psychotherapy treatment,
- • At elevated risk for complicated alcohol withdrawal
- • Past-year drug injection.
About University Of Michigan
The University of Michigan, a leading academic institution renowned for its commitment to advancing healthcare and medical research, serves as a prominent clinical trial sponsor. With a robust infrastructure that supports innovative research initiatives, the university leverages its multidisciplinary expertise to conduct a wide array of clinical trials aimed at improving patient outcomes and advancing medical knowledge. Through its state-of-the-art facilities and collaborative environment, the University of Michigan fosters partnerships between researchers, clinicians, and industry leaders, ensuring the development of cutting-edge therapies and interventions that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Ann Arbor, Michigan, United States
Patients applied
Trial Officials
Allison Lin, MD
Principal Investigator
University of Michigan
Erin Bonar, PhD
Principal Investigator
University of Michigan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials